Medicare GLP-1 coverage 2026: what the $50 bridge program means for you

TL;DR

Starting July 1, 2026, eligible Medicare Part D beneficiaries can access Wegovy (semaglutide) or Zepbound (tirzepatide) for $50 per month through a temporary CMS bridge program running through December 2026 - but the payments do not count toward your out-of-pocket maximum, and your access may not continue into 2027 without a plan switch.

If you are on Medicare and have been watching GLP-1 medications like Ozempic and Wegovy from the sidelines because the $970-per-month list price is simply impossible, a significant policy change takes effect on July 1. The Centers for Medicare and Medicaid Services (CMS) is launching a temporary bridge program that caps your monthly cost at $50 for two specific GLP-1 weight-loss medications. This is the most meaningful access shift for Medicare beneficiaries seeking GLP-1 therapy since these drugs were approved.

Here is the full picture - including the parts the headlines are leaving out.

What the Medicare GLP-1 Bridge program covers

The bridge program covers two medications specifically:

• Wegovy - injectable semaglutide 2.4 mg (Novo Nordisk) and the oral Wegovy tablet
• Zepbound KwikPen - injectable tirzepatide (Eli Lilly)

Notice what is not on the list. Ozempic (semaglutide approved for type 2 diabetes) and Mounjaro (tirzepatide approved for type 2 diabetes) are not included because Medicare Part D already has pathways for covering GLP-1 drugs when prescribed for diabetes. The bridge program specifically addresses the weight-loss indication gap - the long-standing policy that excluded GLP-1 obesity treatment from standard Part D coverage.

Your cost under the program: $50 flat per month. CMS pays the remaining approximately $245, covering the gap between your copay and the negotiated program rate.

The catch: out-of-pocket costs do not count toward your maximum

This is the detail buried in the fine print. Under normal Medicare Part D, your copayments and cost-sharing accumulate toward your True Out-of-Pocket (TrOOP) limit. Once you hit that threshold, your catastrophic coverage kicks in. Payments made under the GLP-1 Bridge program do not count toward TrOOP.

For most people who are only taking a GLP-1 medication and a few generics, this may not matter in practice. But if you have multiple expensive medications and your TrOOP calculation matters to you - particularly if you have reached catastrophic coverage in prior years - the bridge program payments will not help you get there faster.

The continuity risk in 2027

The bridge program runs July through December 2026. It is explicitly temporary. What happens January 1, 2027?

CMS has outlined a pathway called the BALANCE model for 2027 onward, which integrates GLP-1 drug coverage with mandatory lifestyle support programs. But BALANCE is not yet operational, and the details of how beneficiaries transition from the bridge to permanent coverage are still being finalized at time of writing.

The practical risk: if you enroll in the bridge program through your current Part D plan, that plan may not include Wegovy or Zepbound on its standard formulary for 2027. During the Open Enrollment Period in fall 2026 (October 15 - December 7), you will need to actively check whether your plan will continue covering your GLP-1 medication at an affordable rate into 2027. Failing to switch to a plan with GLP-1 coverage could mean losing access or facing full list price on January 1.

How GLP-1 coverage works across different insurance types

Medicare is not the only coverage question worth understanding in 2026. The broader insurance picture is fragmented:

Private and employer insurance

Most employer-sponsored and marketplace plans still exclude GLP-1 medications for weight loss, or cover them with heavy prior authorization requirements. When covered, prior authorization typically requires documented BMI above 30 (or above 27 with a comorbidity) and reauthorization every 6 to 12 months demonstrating ongoing weight loss. The out-of-pocket costs even with coverage can be substantial.

Medicaid

Only 13 states covered GLP-1 medications for obesity as of January 2026 - including Massachusetts, Michigan, and Virginia. Four states eliminated coverage entirely. If your state does not cover GLP-1s for obesity and you have a weight-related comorbidity like sleep apnea or prediabetes, your prescriber may be able to document the diabetes or cardiovascular indication to access coverage that way.

Cash pay

Without any insurance coverage, GLP-1 medications run approximately $970 per month at list price. Both Novo Nordisk and Eli Lilly have savings programs for commercially insured patients who still face high out-of-pocket costs, but these programs do not apply to Medicare or Medicaid beneficiaries.

Steps to take before July 1

If you are a Medicare Part D beneficiary who wants to access the bridge program from day one, here is what to do now:

• Contact your Part D plan and confirm they are participating in the GLP-1 Bridge program and which specific drugs are covered under it.
• Ask your doctor for a prescription now if you do not already have one - prior authorization processes can take weeks, and you want approvals in place before July 1.
• Ask specifically whether the bridge program requires a prior authorization step or whether the $50 copay is automatic through participating pharmacies.
• Flag the Open Enrollment Period (October 15 - December 7, 2026) in your calendar now. You will need to evaluate whether your current plan will cover your GLP-1 medication affordably into 2027.
• If your prescriber suggests Ozempic for weight loss rather than Wegovy, clarify that the bridge program covers Wegovy specifically - the weight-loss-approved formulation matters for coverage.

Why access matters for people already on GLP-1 therapy

If you are already paying full price for Wegovy or Zepbound and you turn 65 this year, or you are transitioning from employer insurance to Medicare, the bridge program is directly relevant to you. The transition from commercial coverage (where savings programs may have offset much of your cost) to Medicare (which until now covered none of it) has caused many patients to discontinue their medication. Stopping GLP-1 medications abruptly is associated with significant weight regain - research shows patients can regain two-thirds of their lost weight within a year of stopping.

Continuity of access is a real clinical concern, not just a cost issue. The bridge program addresses one piece of that - the affordability barrier from July through December 2026. The harder piece is what happens in January 2027, and that requires proactive planning during fall Open Enrollment.

Beyond cost and access, anyone on long-term GLP-1 therapy - at any age and under any insurance structure - faces the nutritional consequences of sustained reduced appetite. Eating significantly less over months means taking in less vitamin B12, vitamin D, iron, and magnesium. These gaps do not announce themselves loudly, but they accumulate. Planning for them proactively is part of staying well on these medications for the long term.

Frequently asked questions

Does Medicare cover Ozempic for weight loss in 2026?

Ozempic (semaglutide for type 2 diabetes) is not included in the GLP-1 Bridge program - that program covers Wegovy (semaglutide for weight loss) and Zepbound KwikPen (tirzepatide for weight loss). Medicare Part D does cover Ozempic when prescribed for type 2 diabetes under standard drug coverage. The access gap the bridge program addresses is specifically the weight-loss indication for obesity-only patients.

How do I sign up for the Medicare GLP-1 Bridge program?

You do not sign up separately - access is through your existing Part D plan if it participates. Contact your Part D insurer to confirm participation and the prior authorization requirements. Your prescriber will need to document your eligibility (BMI and qualifying conditions) as part of the authorization process.

What happens to my GLP-1 coverage after December 2026?

The bridge program is temporary and runs through December 31, 2026. CMS has outlined a longer-term BALANCE model for 2027 that pairs GLP-1 coverage with lifestyle support programs, but details are still being finalized. Use the fall 2026 Open Enrollment Period (October 15 - December 7) to select a Part D plan that will cover your medication into 2027.

What vitamins should Medicare patients on GLP-1 medications take?

People on GLP-1 medications eat significantly less, which reduces intake of every nutrient. Vitamin B12, vitamin D, iron, and magnesium are most commonly flagged in clinical literature as deficiency risks on sustained GLP-1 therapy. Ask your doctor about baseline blood work after 3 to 6 months on the medication, and discuss whether supplementation makes sense for your specific situation.